Journal
CLINICAL CANCER RESEARCH
Volume 15, Issue 21, Pages 6490-6494Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-09-0251
Keywords
-
Categories
Funding
- Melanoma and Skin Cancer Research Institute Sydney
- Hunter Melanoma Foundation, NSW
- National Health and Medical Research Council, Australia
- Cancer Institute
- National Health and Medical Research Council
Ask authors/readers for more resources
Purpose: Lactate dehydrogenase (LDH) levels in blood of patients with melanoma have proven to be an accurate predictor of prognosis and response to some treatments. Exclusion of patients with high LDH levels from many trials of new treatments has created a need for treatments aimed at patients with high LDH levels. This article reviews the metabolic basis for the association of LDH with prognosis and the treatment initiatives that may be successful in this patient group. Experimental Design: Review of current literature on the topic. Results: A number of new treatment initiatives based on manipulation of metabolic pathways in melanoma cells are now available and await evaluation in well-designed clinical trials. Conclusions: Different cancers may require different metabolic approaches for effective treatment. In view of the high rate of glycolysis in most melanoma cells, approaches based on inhibition of acid excretion from the cells seem particularly attractive. (Clin Cancer Res 2009;15(21):6490-4)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available